TrialThe Journal of infectious diseases2024

The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth.

Kristin G Nore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.